COMPOSITIONS AND METHODS FOR DIAGNOSING PROSTATE CANCER USING A GENE EXPRESSION SIGNATURE
Today’s patent was invented by Michaela Bowden, Svitlana Tyekucheva, Massimo Loda, and Lorelei Mucci on January 26, 2021, bearing patent no. US10900086.
The present invention relates to compositions and methods and for the diagnosis, prognosis, and treatment of prostate cancer. The invention is based upon the identification of a gene expression signature that predicts the likelihood that prostate cancer will metastasize. Provided is a method of determining whether prostate cancer in a subject will metastasize. Also provided are compositions comprising a prostate cancer-associated gene. Also provided are kits comprising a package with a prostate cancer-associated gene.